Synonyms: CL 227,193 | CL-227193 | PIPC | T-1220 | Tazocin® (piperacillin + tazobactam)
piperacillin is an approved drug (FDA (1981), UK (2011))
Compound class:
Synthetic organic
Comment: Piperacillin is a broad-spectrum semisynthetic, ampicillin-derived antibacterial.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Piperacillin (as the sodium salt) is used to treat moderate-to-severe infections due to susceptible organisms. In the UK, piperacillin is approved in a number of combination products with tazobactam, which are all administered intravenously (e.g. Tazocin). Tazocin is indicated for the treatment of severe pneumonia, complicated urinary tract infections, complicated intra-abdominal infections, complicated skin and soft tissue infections, or bacteraemia that arises from any of these infections. The UK National Institute for Health and Care Excellence (NICE) recommends piperacillin-tazobactam as initial empiric treatment for patients with suspected neutropenic sepsis [2]. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com |